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Background: The efficacy of topical ophthalmic corticosteroids depends upon small modifications in preparations,
such as drug concentration.
The aim of this study was to confirm that hydrocortisone acetate (HC-ac) ophthalmic ointments of 2.5% and 1% are
more effective than a 0.5% eye ointment.
Methods: In this randomized, double-blind, placebo-controlled, parallel-group clinical study, the change of signs
and symptoms of acute inflammation of the ocular surface and adnexa was evaluated in 411 subjects.
Results: Median time to clinically relevant response as estimated by 50% reduction in clinical signs and symptoms
(CSS) total score over the entire trial was similar for subjects treated with HC-ac 2.5% (73.5 h) and for subjects
treated with HC-ac 1.0% (67.7 h) and was considerably and significantly longer for subjects treated with HC-ac 0.5%
(111.8 h) [p < 0.001 for both dosages]. All trial medications were safe and well tolerated.
Conclusion: Hydrocortisone acetate 2.5% and Hydrocortisone acetate 1% eye ointments are efficacious and safe
treatments for acute inflammations of the ocular surface or adnexa, and showed significantly better efficacy than a
control group treated with Hydrocortisone acetate 0.5% therapy.
Trial registration: Current Controlled Trials ISRCTN15464650.
Keywords: Ophthalmic corticosteroids, Hydrocortisone acetate, Ocular surface, Adnexa, Acute inflammation, Clinical
study, Eye ointment, Adaptive design, Treatment outcomeBackground
Allergic eye inflammation is a localized allergic condi-
tion that is frequently associated with rhinitis and occa-
sionally with asthma but often observed as the only
prevalent allergic sensitization. Ocular allergic symptoms
are estimated to be present in 40%–80% of the affected
individuals [1,2]. Allergic eye diseases include a collec-
tion of clinical entities with variable presentation [3].
The most characteristic symptom of allergic conjunctiv-
itis is itching, which is caused by the release of histamine
and other mediators from specifically activated mast* Correspondence: d.gross@ursapharm.de
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distribution, and reproduction in any mediumcells after allergen exposure [2,4,5]. Other signs and
symptoms include redness, chemosis, tearing, a burning
sensation, photophobia, papillary hypertrophy of the tar-
sal conjunctiva, eyelid and/or conjunctival edema [2].
Symptoms of seasonal allergic conjunctivitis (SAC) are
generally more severe in comparison to perennial aller-
gic conjunctivitis (PAC) [2,6].
On the other hand, blepharitis is an inflammatory
condition of the eyelid margins that might be accom-
panied by an inflammation of the conjunctiva (blepha-
roconjunctivitis). The main goal of the treatment of al-
lergic eye diseases is to reduce the inflammation early
and to prevent complications, which can blur vision or
cause dry eyes [2,7]. The most effective anti-inflammatorytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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acute and severe forms of allergic reactions. Additionally,
patients not responsive to other therapies benefit from
corticosteroids [6,8].
Treatment of blepharitis, on the contrary, relies on
eyelid hygiene, gentle lid massage, and warm com-
presses. Recently, the authors demonstrated the effect-
iveness of the antiseptic bibrocathol for the treatment
of blepharitis [9]. Topical antibiotics might be used in
patients who do not respond to eyelid hygiene and, in
severe cases, oral antibiotics and topical steroids may
also be beneficial [8].
Corticosteroids are potent anti-inflammatory drugs
used for the treatment of allergic conjunctivitis and
other non-infectious inflammatory diseases of the anter-
ior eye. Topical ophthalmic steroids inhibit the produc-
tion of various inflammation-causing mediators, such as
prostaglandins, which are released when the eye reacts
to allergens. Despite being important and effective thera-
peutic candidates for the treatment of allergic conjunc-
tivitis [6], their use is typically reserved for patients not
responsive to other therapies or for use in acute and
severe forms of allergy because of the potential side-
effects (e.g., increased intraocular pressure (IOP) and
risk of cataract formation) [8]. We report the results
from a randomized, controlled clinical trial to investigate
whether higher concentrations of hydrocortisone acetate
in the two eye ointments (i.e. Hydrocortisone acetate
2.5% and Hydrocortisone acetate 1%) are more effective
in improving objective signs and subjective symptoms of
non-infectious disease of the eye and ocular adnexa than
the lower-concentrated Hydrocortisone acetate 0.5% eye
ointment (concentration – response relationship).
Methods
This was a multicenter, randomized, double-blind, parallel-
group, active-control, study designed to evaluate the effects
of HC-ac 2.5%, HC-ac 1.0%, and HC-ac 0.5% on relief of
clinical signs and symptoms in patients with acute inflam-
mation of the ocular surface or adnexa. The objective of
the study was to show superior efficacy of at least one of
the HC-ac dosages compared to the active control group,
HC-ac 0.5%.
The eye ointments with Hydrocortisone acetate 2.5%
and 1% are products of URSAPHARM Arzneimittel
GmbH, Saarbruecken, Germany with the tradename
Hydrocortison-POS® N 2.5% resp. 1%. The comparator
product, eye ointment with 0.5% hydrocortisone acetate, is
marketed as Ficortril® eye ointment 0.5% and manufac-
tured by Dr. Mann Pharma, Berlin.
The study was conducted at 10 trial centers in the
Ukraine according to the International Conference on
Harmonisation - Good Clinical Practices guidelines
(ICH-GCP) and in compliance with national Ukrainianlaw and regulations. This includes that each patient con-
firmed his/her informed consent in participating in this
study in writing. The study was approved both by the
Central Ethics Committee at Kyiv (Ukraine) and by the
local ethics committees of each investigator.
Subjects were randomly assigned to one of the three
active treatments in a ratio of 1:1:1. Research Pharma-
ceutical Services prepared a randomization list with
balanced blocks of 6 subjects each, different blocks were
used for subjects with or without pretreatment yielding a
respective balance (stratification). Trial medication in all
three treatment arms was of identical appearance, shape,
and size; and the 3 medications were indistinguishable
regarding consistency, color, smell, and viscosity.
Inclusion criteria were: Female or male outpatients; 18
to 75 years; presence of non-infectious disease of the eye
and ocular adnexa, i.e. seasonal or perennial allergic
conjunctivitis; acute allergic blepharitis; blepharocon-
junctivitis; allergic lid edema; acute inflammation of the
ocular surface, or adnexa for which topical steroid treat-
ment was advisable. In addition, a minimum symptom
intensity was required, as assessed by the “Clinical Signs
and Symptoms” (CSS) total score ≥ 10 (maximum 30),
and with at least one item scored of “moderate” or “severe”
intensity.
Exclusion criteria were: Any systemic disease that
prohibited steroid treatment; any contraindication for
the use of steroids; pretreatment with systemic or top-
ical steroids 1 month prior to, or concomitantly during
trial participation. Further exclusion criteria were: Con-
comitant treatment with corticosteroids other than trial
medication (e. g. corticosteroids for inhalation), mast-cell
stabilizers, and other anti-allergens (except antihistamines,
analgesics, anti-inflammatory drugs, anti-rheumatic drugs,
and immunosuppressants); findings on fluorescein corneal
staining at baseline (which prohibited steroid treatment);
eye discharge (yellowish) with score ≥ 1 at baseline as
assessed by the investigator; ocular injury and/or ocular
surgery within 3 months prior to trial participation; wore
contact lenses, and had a change in eye hygiene measures
after study initiation.
The planned treatment duration was 14 days with 6
visits (Baseline [V0], control visits on Days 2 [V1], 4 [V2],
7 [V3], and end of trial visit if CSS = 0 on Day 10 ± 1 [V4],
otherwise end of trial visit on Day 14 [V5]). 1 cm of eye
ointment as randomized was administered in the lower
conjunctival sac of each affected eye at baseline. The
medication was applied twice daily (morning and evening
at bedtime) for 10 consecutive days, with the option to
prolong treatment to 14 days, until resolution of all signs
and symptoms, or study end.
The primary objective of this trial was to demonstrate
superiority of HC-ac 2.5% and 1.0% versus HC-ac 0.5%
and, if possible superiority of HC-ac 2.5% versus HC-ac
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score. Secondary objectives were to assess further mea-
sures of efficacy, tolerability, and safety.
The CSS total score comprised 6 objective signs (con-
junctival hyperemia, discharge, watering eyes, chemosis,
red eyelids, swollen eyelids) and 4 subjective symptoms
(foreign body sensation, itching, ocular pain, and dry-eye
sensation) assessed at each trial visit (0–3 points per
signs/symptoms, the higher the worse, maximum 30
points) (see Table 1). Objective signs were assessed by
the investigator on the basis of a slit lamp examination
of the eye with the highest CSS total score at baseline
(if the score was equal for both eyes at baseline, one of
the eyes was chosen deliberately) and subjective symp-
toms were assessed by interviewing the subjects.
As secondary efficacy variables the difference to base-
line in CSS total score, the CSS subscores signs and
symptoms, the time to first occurrence of at least 50%
reduction in each CSS subscore, remitter (CSS = 0) rates
at study end, the scores of individual CSS items at each
trial visit, and the treatment duration until complete re-
mission (CSS = 0) were analysed.
Safety parameters consisted of visual acuity test, IOP
measurement (measured by tonometry) at visits V0, V4
and V5; adverse events (AEs); and global rating of toler-
ability (V4 and V5).
The data from subjects randomized and exposed were
analysed (intent to treat [ITT] population). The time to
first occurrence of at least 50% reduction in CSS total
score was used to hierarchically test three hypotheses
(H1: HC-ac 2.5% ≥HC-ac 0.5%, H2: HC-ac 1% ≥HC-ac
0.5%, and H3: HC-ac 2.5% ≥HC-ac 1%) using Kaplan-
Meier statistics and comparing each of the treatmentTable 1 Grading of parameters to evaluate efficacy
Signs and symptoms Degree (=item value)
0 1
Symptoms
Foreign body sensation in
the eye
not present not disturbing
Itching not present not disturbing
Ocular pain not present not disturbing
Dry-eye sensation absent not disturbing
Signs
Conjunctival hyperaemia vessel normal some vessel definitely
injected
Discharge (yellowish) not present poorly visible
Watering eyes absent Nnot disturbing
Chemosis not present poorly visible
Red eyelids not present poorly visible
Swollen eyelids not present poorly visible (not disturbigroups pair-wise with the Cox-variant of the Log-Rank
test. If ≥ 50% reduction was not reached during the time
under treatment exposure, the subject was censored at
the time of the last observation. The study followed a
2-stage adaptive design [10,11] with sample-size adjust-
ment after the planned interim analysis. For the final
hypotheses testing, the p-values of the 2 parts of the
study were calculated separately and then combined
using Fisher’s combination rule (p* = p1 × p2) and
adjusted for type I error probability cα ≤ 0.0038.
Secondary efficacy variables were compared between
groups using ANCOVA with treatment as a factor and
the baseline values as a covariate. The 2-sided 95% con-
fidence intervals as well as the p-value for the baseline
adjusted LS-means of all pair-wise differences between
groups were calculated. Time to event analyses (50%
improvement, CSS = 0) used the Kaplan-Meier-statistics
and compared each of the treatment groups pair-wise
with the Log-Rank-Test. Pair-wise comparisons of re-
sponders and remitters were performed with the chi2
test or Fisher’s exact test. Global ratings of efficacy by in-
vestigators and subjects were compared pair-wise using
Wilcoxon U-tests.
Missing secondary efficacy variables were replaced using
the last-observation-carried-forward (LOCF) approach.
The sample size estimation was based on the following
assumptions: 10 or 14 days of observation; reduction of
CSS total score by at least 50% in 85% of the subjects
treated with HC-ac 2.5% and in 65% of subjects treated
with HC-ac 0.5% after two days of treatment; signifi-
cance level α = 0.025 (one-sided); power = 90%; drop-
out rate during 10 days = 5%. This yielded, under the








clearly visible over 2 mm thick
disturbing Iintolerable
clearly visible very strong
clearly visible very strong
ng) clearly visible (disturbing) very strong (eye opening difficult)
Table 2 Demographic data at baseline (ITT)






Sex Male n (%) 58 (43.6) 61 (43.6) 56 (40.6)
Female n (%) 75 (56.4) 79 (56.4) 82 (59.4.)
Age (years) Mean ± SD 46.5 ± 17.2 49.36 ± 15.5 47.0 ± 16.3
Median 47 50 48
Range 17 – 76 18 – 75 20 – 75
BMI (kg/m2) Mean ± SD 25.78 ± 3.93 25.76 ± 3.26 25.60 ± 3.99
Median 25.54 25.86 25.40
Range 17.30-40.80 19.10-35.02 17.01-44.78
Study eye Left n (%) 59 (44.4) 62 (44.3) 68 (49.3)
Right n (%) 74 (55.6) 78 (55.7) 70 (50.7)
Diagnosis
Allergic conjunctivitis n (%) 22 (16.5) 25 (17.9) 28 (20.3)
Allergic blepharitis n (%) 45 (33.8) 59 (42.1) 56 (40.6)
Allergic blepharo-conjunctivitis n (%) 66 (49.6) 56 (40.0) 54 (39.1)
BMI = body mass index; n = number of subjects; % percent of subjects in each group; SD: standard deviation.
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the interim analysis within the 2-stage adaptive design
that was performed by an independent statistician, the
trial could not be terminated prematurely due to rejec-
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Treatment HC-ac 2.5%
Figure 1 Time to ≥ 50% reduction in CSS total score.the sample size requested at least further 50 subjects
per arm to be included into a second part of the study.
To be on the safe side, it was decided to include 70
additional subjects per arm in the second part of the
study, leading to a total of 411 subjects in the trial.e [h]
160 180 200 220 240 260 280 300
HC-ac 1.0% HC-ac 0.5%
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A total of 411 subjects were enrolled in the study and
randomized to the HC-ac 0.5% (n = 133), the HC-ac 1%
(n = 140), or the HC-ac 2.5% (n = 138) arms. All of the sub-
jects received at least one dose of the trial medication and
were available for the safety (SAF) and efficacy (intent-to-
treat [ITT]) analysis (SAF and ITT populations, respectively).
A total of 398 subjects completed the study: 129 in the
HC-ac 0.5% arm, 135 in the HC-ac 1% arm, and 134 in
the HC-ac 2.5% arm. The remaining 13 subjects prema-
turely discontinued treatment during the first part of the
study: 4 in the HC-ac 0.5% arm, 5 in the HC-ac 1% arm,
and 4 in the HC-ac 2.5% arm. Main reasons for discon-
tinuation were request of the subjects (n = 11; 4 in the
HC-ac 0.5% arm, 4 in the HC-ac 1% arm, and 3 in the
HC-ac 2.5% arm) or AEs (n = 2; 1 in the HC-ac 1% arm,
and 1 in the HC-ac 2.5% arm).
Baseline demographic and clinical characteristics are
summarized in Table 2.
Median treatment duration was 10 days in the 2.5%
and 1.0% HC-ac and 11 days in the HC-ac 0.5% arm.
Efficacy
The results of the three hypotheses related to the pri-














































HCac 2.5% HCac 1.0% HC
Baseline Visit 1 (Day 2) Visit 2 (Day 4) Vi
Figure 2 Change from baseline to all post-baseline visits in CSS totalestimated by the Kaplan-Meier statistic to 50% reduction
in CSS total score over the entire trial (ITT, N = 411)
was similar for subjects treated with HC-ac 2.5% (73.5 h)
and for subjects treated with HC-ac 1.0% (67.7 h) and
was considerably and significantly longer for subjects
treated with HC-ac 0.5% (111.8 h) [p < 0.001] (Figure 1).
Baseline mean values of CSS sum score were very
similar between treatments (HC-ac 2.5%: 16.1 points,
HC-ac 1.0%: 16.3 points, and HC-ac 0.5%: 16.3 points).
The mean reduction of the CSS total score between each
trial visit and baseline increased progressively for all
treatments (Figure 2); however, this reduction was
higher in subjects treated with HC-ac 2.5% and HC-ac
1% compared with subjects treated with HC-ac 0.5%
from Day 2 (Visit 1) to Day 10 (Visit 4) [p ≤ 0.001]. In
addition, subjects treated with HC-ac 2.5% experienced
a greater reduction in the score than subjects treated
with HC-ac 0.5% in the last observation carried forward
(LOCF) analysis (p = 0.022).
The time (h) to first occurrence of at least 50% reduc-
tion in CSS total sum score and the two subscores
(Table 3, Figure 1), as well as the time to complete re-
mission (Table 3) was shorter when being treated with
HC-ac 2.5% and 1% than when being treated with HC-












sit 3 (Day 7) Visit 4 (Day 10) Visit 5 (Day 14) LOCF
score.
Table 3 Time (hours) to ≥50% reduction and to complete







Time to 50% reduction from baseline (days)
CSS total
Mean ± SD 112 ± 47 81 ± 36 81 ± 38
Median 112 68 74
Range 17 – 217 21 – 174 16 – 235
CSS objective signs
Mean ± SD 114 ± 51 83 ± 41 83 ± 39
Median 121 72 82
Range 15 – 272 18 – 238 16 – 183
CSS subjective symptoms
Mean ± SD 110 ± 48 82 ± 41 80 ± 42
Median 110 68 69
Range 17 – 224 18 – 253 14 – 266
Time to complete remission (days)
CSS Total = 0
Mean ± SD 250 ± 55 232 ± 45 228 ± 39
Median 240 220 220
Range 70 – 342 72 – 379 121 – 342
CSS objective signs subscore = 0
Mean ± SD 249 ± 56 232 ± 45 227 ± 40
Median 240 220 220
Range 70 – 342 72 – 379 121 – 342
CSS subjective symptoms subscore = 0
Mean ± SD 248 ± 586 224 ± 52 220 ± 48
Median 240 220 219
Range 70 – 342 72 – 379 70 – 342
CSS Clinical signs and symptoms n = number of subjects; SD standard
deviation; range: minimum – maximum.
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of HC-ac 1.0% and 2.5%.
Almost all subjects had responded to treatment medi-
cation (CSS improvement by ≥ 50%) on Day 10 (Table 4)
and no notable differences were observed among treat-
ments. No differences were observed between theTable 4 Responder and remitter rates after 10 days of
treatment






Responders n (%) 129 (97.0) 136 (97.1) 135 (97.8)
Remitters n (%) 76 (57.1) 116 (82.9) 119 (86.2)
n = number of subjects; % percent of subjects in each group.
A responder was defined by a ≥ 50% improvement in the CSS total score
between Day 10 visit and baseline.
A remitter was defined by a CSS total score = 0 (symptom-free) at the Day
10 visit.proportions of remitters (CSS = 0) in the HC-ac 2.5%
and HC-ac 1% treatment groups. However, the propor-
tion of remitters was higher in both the HC-ac 2.5% and
HC-ac 1.0% treatment groups than in the HC-ac 0.5%
treatment group (p < 0.001).
At baseline, mean average scores for each of the sub-
jective symptoms and objective signs decreased progres-
sively in all treatment groups throughout the study visits
achieving maximum improvement on Day 10. Again, this
reduction was greater when being treated with HC-ac 2.5%
and 1% than when being treated with HC-ac 0.5% for the
following items: foreign body sensation (p < 0.001 both),
itching (p < 0.001 both) and dry eye (p = 0.004 both),
as well as conjunctival hyperemia (p < 0.001 both), che-
mosis (p = 0.009 and p = 0.011, respectively), red eye lids
(p < 0.001 both), and swollen eye lids (p < 0.001 both).
The reduction of yellowish discharge was greater only
in subjects treated with HC-ac 2.5% than those treated
with HC-ac 0.5%.
The patients were treated in different seasons of the
year which correlated with the severity of symptoms at
baseline and the time of reduction of symptoms. How-
ever, an influence of the season on the differences of the
three treatments could not be observed.
All trial medications were safe and well tolerated. No
deaths or serious adverse events (SAEs) were reported
throughout the study, and the incidence of subjects with
AEs was 2.2%. In two subjects, the AEs lead to treatment
interruption and discontinuation. One of these subjects
was treated with HC-ac 2.5% and experienced increased
lacrimation (mild); the other was treated with HC-ac 1%
and had conjunctival hyperemia (moderate) and increased
lacrimation (mild). Other AEs reported during the study
were discomfort or pruritus at the site of application. No
clinically relevant changes during treatment were observed
in visual acuity measures and intraocular pressure (IOP)
values.
Discussion
This multicenter, randomized, double-blind, parallel-
group, active-controlled study in subjects with acute
inflammation of the ocular surface or adnexa could
demonstrate a faster (by 31 hours) clinically relevant
(50% of baseline severity) improvement of objectively
determined signs and subjectively reported symptoms
when treated with two hydrocortisone eye ointments in
concentrations of 2.5 and 1.0% (HC-ac 2.5%, HC-ac
1.0%) compared with a lower concentrated preparation
(HC-ac 0.5%). There was no difference in this primary
endpoint between the 1.0% and the 2.5% concentration.
This observation indicates that there is no linear dose–
response-relationship for this type of treatment. All
secondary outcome measures consistently supported
the primary finding, showing improvement in the total
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ive symptoms, and in most of the individual signs and
symptoms. Of note, the rate of symptom-free subjects
after the maximum treatment duration of 10 days was
83% and 86% in the 1.0% and the 2.5% concentration
arms, respectively: these rates were approximately 25%
higher than those in the control group (57%). At the











































































































































Figure 3 Change from baseline to Day 10 in CSS total score for subjeexceptions (HC-ac 0.5%: 12.3%, HC-ac 1.0%: 6.4%; HC-
ac 2.5%: 2.2%) all subjects were symptom-free.
Topical eye ointments are available with different con-
centrations of hydrocortisone acetate. The findings of
this study indicate that treatment with corticosteroids is
highly effective in subjects with allergic conjunctivitis
[8]; however, they also show that higher concentrations
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sus 4.7 [0.5%] days, median); time to complete remission
(9.2 [1% and 2.5%] days versus 10.0 [0.5%] days) and in
the rates of symptom-free subjects ten days after start of
treatment (see above). In all analyses, treatment with 1%
and 2.5% hydrocortisone helped to gain approximately
one day with less severe or no symptoms compared to
the eye ointment with the lowest concentration. The
advantage of more than 1.5 days of the two Hydrocorti-
sone acetate concentrations in the time to response is
expressed in the hazard ratios that indicate a 2.4-fold
(95%-CI: 1.7;3.3; HC-ac 2.5%) or a 2.2-fold (95%-CI: 1.6;
3.1; HC-ac 1.0%) higher chance to achieve an early rele-
vant relief (≥50% of baseline severity) from symptoms
than under the lower-concentrated hydrocortisone.
Regarding the relevance of allergic ocular diseases on
quality of life or work productivity [12], such a faster
recovery, could imply a significant reduction of indirect
health costs as well as shorter duration of burdens of
the disease for the affected subjects. Such data were not
included in our study design; however, if in accordance
with the clinical data, they would support the importance
of the described differences between the two Hydrocorti-
sone acetate treatments and the Hydrocortisone acetate
0.5% treatment even more strongly, and are suggested to
be included in future trials.
The desired rapid treatment success could be achieved
by doubling the concentration of 0.5% (Hydrocortisone
acetate) to 1% (HC-ac 1.0%) hydrocortisone, a further
increase of hydrocortisone concentration to 2.5%
(HC-ac 2.5%) did not contribute additional substantial
benefit.
Tolerability was not a major treatment issue, with only
2.2% of subjects in total experiencing mild to moderate
AEs: increased lacrimation, conjunctival hyperemia, and
pruritus/discomfort at the application site. Only two sub-
jects discontinued from the study prematurely because of
AEs. In addition, visual acuity and IOP values were within
the normal ranges at baseline and at the end of the study,
and no clinically relevant changes were reported through-
out the 2-week treatment duration. No instances of cata-
ract formation were observed.
Subjects with baseline moderate to severe symptoms
of acute inflammation of mostly allergic blepharocon-
junctivitis (43%), as well as allergic blepharitis (39%)
or allergic conjuncitivitis (18%) were treated. Most
severe symptoms were foreign body sensations in the
eye, itching, red or swollen eyelids, and conjunctival
hyperemia (Figure 3), whereas yellowish discharge was
present in only a few subjects. Non-response to other
therapies was not an inclusion criterion; therefore,
our conclusions cannot be extended to this treatment-
refractory sub-population of subjects with allergic
conjunctivitis.Conclusion
We conclude from this trial that hydrocortisone eye oint-
ment in higher concentration of at least 1% is superior to
a frequently used 0.5% concentration with regard to earlier
onset of clinically relevant improvement and shorter time
to complete healing in subjects with acute non-infectious
inflammation of the ocular surface or adnexa. The higher
concentrations, 2.5% and 1% were equally effective. All
hydrocortisone concentrations were safe and well toler-
ated, none of the known risks of ketone-corticosteroids
were observed during this 2-week treatment period.
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